Smith & Nephew (LSE:SN.) cut its 2026 outlook last week and confirmed that talks with Johnson & Johnson over a potential orthopaedics combination have ended. The twin announcements leave the FTSE 100 medical technology group's long-standing dividend, which has barely grown in the past year, resting on a Business whose future shape remains unsettled.

A long record, but growth has stalled

As of 7 October 2026, Smith & Nephew was paying an annual Dividend of 29.0p per share, with the latest distribution at 11.8p. The company reports in US dollars, so these sterling figures are affected by currency movements. The trailing 12-month Yield is 2.9% and the indicated yield is 3.0%. The small gap between the two suggests the payout has not changed materially relative to the share price.

The headline attraction is durability. The group has paid dividends continuously for 42 years, a long record by any standard. Growth has been far less impressive: a year-on-year increase of just 0.1%, and only one year of continuous growth. That combination describes a company that protects its payout reliably but has found little scope to increase it, leaving investors with a dividend that has been losing ground to Inflation in real terms.

Because the board sets the dividend in dollars, sterling holders see a figure that moves with the Exchange Rate as well as with company decisions. A flat dollar payment can therefore look like a small rise or fall in pence, which is worth remembering when reading year-on-year comparisons for a group with this currency profile.

How cover protects the payout

The Payout Ratio of 53.5% is comfortable, equivalent to cover of about 1.9 times. Cover simply measures how many times Earnings could pay the dividend, and the payout ratio is its mirror image: the share of profit distributed to shareholders. At roughly half of earnings, there is a reasonable cushion even after the reduction in profit expectations.

For a medical technology business such as Smith & Nephew (LSE:SN.), that cushion matters. Demand for joint replacement, sports medicine and wound care is tied to ageing populations and elective surgery volumes, which gives Revenue a steady character over the longer run, even though individual quarters can be uneven. But earnings can still be pressured by pricing, competition and the mix of products sold, as this year's US trading has shown. A payout set well below earnings gives the board room to hold the dividend through a patch of weaker profit without drawing on the balance sheet.

What the third quarter showed

The third-quarter update on 4 November reported revenue of $1,551m, up 3.4% on both an underlying and a reported basis. Beneath that, US knee implants fell 7.3%, and it was weakness in US hips and knees that prompted the change in guidance.

Underlying revenue growth for the full year is now expected at around 3%, down from about 4%. Trading profit is expected to come in at around $1.25bn, compared with about $1.3bn previously, representing growth of around 4%. Management no longer expects a material improvement in US knees and hips during the fourth quarter, and said a headwind from skin substitutes is likely to be towards the upper end of a $20m to $40m range.

The market reaction appeared more forgiving than the news might suggest. The company's US-listed shares were up almost 4% in premarket trading on the day, indicating that some investors may have been focused on the end of the J&J discussions or on a beat against earnings forecasts, rather than on the lower guidance alone.

Orthopaedics in the balance

The bigger strategic question concerns Orthopaedics. Smith & Nephew had approached J&J earlier in the year about a potential combination involving J&J's DePuy Synthes business, as part of its review of Options for the division. Chief executive Deepak Nath described the discussions as intensive, and said a full range of alternatives is still being considered, without offering a likely outcome or timetable. He noted that stranded costs and the expense of setting up a separate business would be relevant to any spin-off.

Those points are central to dividend thinking at Smith & Nephew (LSE:SN.). When a group separates a large division, the remaining company has a different earnings base, a different cost structure and often a different Capital allocation policy. Stranded costs, meaning overheads that were shared and do not disappear with the divested unit, can depress profit for a time. Any change of shape would therefore be expected to prompt a fresh look at how much the business can pay out.

Capital returns have continued in the meantime. A $500m share buyback is on track, with $250m completed by the end of the third quarter, and management expects free Cash Flow of around $750m in 2026. The dividend at its current rate costs far less than that cash flow, which suggests it is not under immediate pressure, and the buyback is funded from the same cash flow, so both returns can continue at present levels.

What to watch

Timetables matter as much as outcomes here. The company has not indicated when a decision will come, so the dividend discussion is likely to stay conditional for some time.

Full-year results will show whether the lowered guidance has been met and whether the board can add to its one-year growth streak. A decision on Orthopaedics would be the most significant event for income investors, because separation could change the group's earnings base and therefore its dividend capacity. Signs of stabilisation in US knees and hips would ease concern, as would progress on the remaining $250m of the buyback.

Investors following Smith & Nephew (LSE:SN.) for income should also keep an eye on currency movements, since the dollar-to-sterling rate affects the pence value of each payment, and on any change in the group's stated approach to balancing dividends against buybacks.